Optivia Biotechonlogy Inc
115 Constitution Drive
Suite 7
Menlo Park
California
94025
United States
Tel: 650-324-3177
Fax: 650-324-1855
Website: http://www.optiviabio.com/
11 articles about Optivia Biotechonlogy Inc
-
BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio
7/9/2018
Acquisition strengthens BioIVT's transporter sciences capabilities and enables it to partner with customers on new drug applications and mechanistic studies related to transporters.
-
Optivia Biotechnology Inc. Launches Screening Service For Transporters As Drug Targets
9/15/2015
-
Optivia Biotechnology Inc. Appoints Dr. Jean-Michel Scherrmann To Scientific Advisory Board
2/11/2015
-
Optivia Biotechnology Inc. Awarded $1.8 Million SBIR Grant to Build Platform for Transforming Central Nervous System (CNS) Disease Drug Discovery and Development
10/2/2013
-
Optivia Biotechnology Inc. Wins CRO Leadership Award from Life Science Leader
6/4/2012
-
Optivia Biotechnology Inc. Awarded $1.85 Million SBIR Grant to Build Comprehensive Platform for Assessing Dangerous Drug-Drug Interactions
4/5/2011
-
Almost 300 New Jobs To Be Created By Three Pharma Firms: Optivia Biotechnology Inc., Global Research Services, LLC, and International Prevention Research Institute (iPRI)
3/17/2011
-
Optivia Biotechnology Inc. Signs Agreement With U.S. FDA to Assess Role of Dietary Supplements in Drug-Induced Liver Injury
2/1/2011
-
University of California, San Francisco (UCSF) and Optivia Biotechnology Inc. Collaborate to Predict Liver Toxicity of Drugs in Development
11/16/2010
-
Optivia Biotechnology Inc. Names Dr. Yuichi Sugiyama to Scientific Advisory Board
11/15/2010
-
Optivia Biotechnology Inc. Launches Comprehensive Assay Suite to Assess Transporter-Related Drug-Drug Interactions and Improve Drug Safety
5/11/2010